Methods and pharmaceuticals for treatment of viral infections of the eye
AssigneeTamir Biotechnology, Inc.
InventorsLuis Squiquera, Jamie Sulley
Life of this patent
Estimating the term…
Abstract
Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
Claims18
A method of treating an adenoviral infection of the eye, comprising the step of administering to the eye a therapeutically effective dose of a ribonuclease that is a member of the ribonuclease A superfamily.
A method for treating an adenoviral infection of the human eye, the method comprising administering an ophthalmic composition to the eye, the composition comprising:
- a. a therapeutically effective dose of a ribonuclease that is a member of the ribonuclease A superfamily and that is non-irritating to the eye as determined using
- i. the Globally Harmonized System of Classification Evaluation Criteria and
- ii. the European Economic Community Ocular Evaluation Criteria;
- and
- b. a vehicle.
A method of treating an adenoviral infection of an eye, the method comprising the step of topically administering to the eye a therapeutically effective amount of a ranpirnase.
Dependencies are inferred from the claim text.